Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting 29.4 percent of Spark’s shares in a tender originally due to end on Wednesday.
Source:: Reuters – Business News
